Who makes BL1107 Low dose?

BL1107 Low dose is developed by Bausch & Lomb Incorporated.

Last reviewed 2026-04-23 · How we verify

BL1107 Low dose

Bausch & Lomb Incorporated · Phase 2 active Small molecule

At a glance

Generic name	BL1107 Low dose
Sponsor	Bausch & Lomb Incorporated
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BL1107 Low dose CI brief — competitive landscape report
BL1107 Low dose updates RSS · CI watch RSS
Bausch & Lomb Incorporated portfolio CI